Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Application of the Formula for Rational Antimicrobial Therapy (FRAT) to Community-Acquired Pneumonia
JM Blondeau1,2* and N Theriault31Department of Clinical Microbiology, Royal University Hospital and the Saskatoon Health Region, Saskatoon, SK, Canada
2Departments of Microbiology and Immunology, Pathology and Ophthalmology, University of Saskatchewan, Saskatoon, SK, Canada
3Collegeville, Pennsylvania, USA
- *Corresponding Author:
- JM Blondeau
Department of Microbiology, Royal University Hospital
103 Hospital Drive, Saskatoon, Saskatchewan, Canada
Tel: 306-655-6943
Fax: 306-655-6947
E-mail: joseph.blondeau@saskatoonhealthregion.ca
Received date: January 17, 2017; Accepted date: January 30, 2017; Published date: February 01, 2017
Citation: Blondeau JM, Theriault N (2017) Application of the Formula for Rational Antimicrobial Therapy (FRAT) to Community-Acquired Pneumonia. J Infect Dis Ther 5:313. doi:10.4172/2332-0877.1000313
Copyright: © 2017 Blondeau JM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Community-acquired pneumonia (CAP) remains a common condition for which patients seek medical advice in the outpatient setting and where antimicrobial agents are prescribed empirically–often based on therapeutic guideline recommendations. Antimicrobial resistance impacts on therapeutic choices as resistance is associated with clinical failure which in turn may impact morbidity and mortality. The Formal for Rational Antimicrobial Therapy (FRAT) considers etiology and antimicrobial susceptibility to generate a factor to predict the likely activity of an antimicrobial agent in CAP or any other infection for which etiology and susceptibility data can be considered. In considering the FRAT formula in CAP, amoxicillin and macrolides offer a predictability of 52.6-78.3% whereas for trimethoprim/sulfamethoxazole the predictability was 45.2% as compared to 90.1% for tetracyclines/doxycycline and 98.2% for levofloxacin (and moxifloxacin) . The FRAT formula clearly differentiates antimicrobial agents based on spectrum of activity and impact of antimicrobial resistance and provides yet another factor for consideration in the selection of an antimicrobial agent for treatment of CAP.
